Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis

Compared with the general population, patients receiving maintenance dialysis are at increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19). Currently, data on severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific immunity post -vaccination in patients on maintenance dialysis are scarce given that the effectiveness of the vaccines has not been ex-plicitly tested in this population due to their common exclu-sion from SARS-CoV-2 vaccination trials. We herein present data of the specific cellular (interferon-gamma and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay) at 4 weeks and 6 weeks following a single dose or a com-plete homologous dual dose SARS-CoV-2 vaccine regimen in 60 adult patients on maintenance dialysis (six with a his-tory of COVID-19). The data was produced in a framework of a project focused on a) quantifying the immune response after full vaccination, b) evaluating the short-term durabil-ity of immune response, and c) examining the reactogenicity of SARS-CoV-2 vaccine regimens in patients on maintenance dialysis. (C) 2022 The Author(s). Published by Elsevier Inc.